ICI-63197
0ICI-63197 is a pharmacological compound developed by ICI, a British chemical company. It is a member of the benzodiazepine class of drugs, which are commonly used for their sedative and anxiolytic effects.
History[edit]
ICI-63197 was first synthesized in the laboratories of ICI in the late 20th century. The compound was part of a series of benzodiazepines developed by the company, which also includes well-known drugs such as diazepam and lorazepam.
Pharmacology[edit]
As a benzodiazepine, ICI-63197 acts on the GABA receptors in the brain. These receptors are responsible for inhibitory neurotransmission, and their activation leads to a decrease in neuronal excitability. This results in the sedative and anxiolytic effects characteristic of this class of drugs.
Clinical Use[edit]
The clinical use of ICI-63197 is not well-documented, as it is not a commonly prescribed drug. However, like other benzodiazepines, it may be used in the treatment of conditions such as anxiety disorders, insomnia, and seizure disorders.
Side Effects[edit]
Potential side effects of ICI-63197 are similar to those of other benzodiazepines and may include drowsiness, dizziness, and dependency with long-term use.
See Also[edit]
References[edit]
